Aileron Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aileron Therapeutics has been growing earnings at an average annual rate of 5.1%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
5.1%
Earnings growth rate
46.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -30.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18
Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13Revenue & Expenses Breakdown
How Aileron Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -29 | 17 | 13 |
| 30 Jun 24 | 0 | -25 | 16 | 9 |
| 31 Mar 24 | 0 | -18 | 13 | 6 |
| 31 Dec 23 | 0 | -16 | 11 | 4 |
| 30 Sep 23 | 0 | -13 | 8 | 4 |
| 30 Jun 23 | 0 | -17 | 9 | 9 |
| 31 Mar 23 | 0 | -24 | 9 | 14 |
| 31 Dec 22 | 0 | -27 | 10 | 18 |
| 30 Sep 22 | 0 | -30 | 10 | 20 |
| 30 Jun 22 | 0 | -30 | 10 | 28 |
| 31 Mar 22 | 0 | -28 | 9 | 19 |
| 31 Dec 21 | 0 | -26 | 10 | 17 |
| 30 Sep 21 | 0 | -24 | 10 | 14 |
| 30 Jun 21 | 0 | -23 | 9 | 5 |
| 31 Mar 21 | 0 | -21 | 9 | 11 |
| 31 Dec 20 | 0 | -21 | 9 | 11 |
| 30 Sep 20 | 0 | -23 | 10 | 9 |
| 30 Jun 20 | 0 | -26 | 11 | 7 |
| 31 Mar 20 | 0 | -29 | 12 | 4 |
| 31 Dec 19 | 0 | -29 | 12 | 0 |
| 30 Sep 19 | 0 | -29 | 13 | 0 |
| 30 Jun 19 | 0 | -29 | 11 | 0 |
| 31 Mar 19 | 0 | -31 | 13 | 0 |
| 31 Dec 18 | 0 | -32 | 12 | 0 |
| 30 Sep 18 | 0 | -31 | 12 | 0 |
| 30 Jun 18 | 0 | -30 | 13 | 0 |
| 31 Mar 18 | 0 | -26 | 10 | 0 |
| 31 Dec 17 | 0 | -23 | 9 | 0 |
| 30 Sep 17 | 0 | -20 | 7 | 0 |
| 30 Jun 17 | 0 | -18 | 6 | 0 |
| 31 Mar 17 | 0 | -19 | 8 | 0 |
| 31 Dec 16 | 0 | -18 | 8 | 0 |
| 30 Sep 16 | 0 | -17 | 8 | 0 |
| 30 Jun 16 | 0 | -16 | 8 | 0 |
| 31 Mar 16 | 0 | -14 | 5 | 0 |
| 31 Dec 15 | 0 | -13 | 5 | 0 |
| 30 Sep 15 | 0 | -13 | 5 | 0 |
| 30 Jun 15 | 0 | -13 | 6 | 0 |
| 31 Mar 15 | 0 | -15 | 6 | 0 |
| 31 Dec 14 | 0 | -16 | 7 | 0 |
| 31 Dec 13 | 22 | 0 | 7 | 0 |
Quality Earnings: ALRN is currently unprofitable.
Growing Profit Margin: ALRN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALRN is unprofitable, but has reduced losses over the past 5 years at a rate of 5.1% per year.
Accelerating Growth: Unable to compare ALRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ALRN has a negative Return on Equity (-30.71%), as it is currently unprofitable.